I am an attending research clinical chemist in the Departments of Laboratory Medicine, Surgery (Urology Service), and Medicine (Genitourinary Oncology Service) at Memorial Sloan Kettering Cancer Center. With my discovery of free PSA and other prostate-related proteins, I am primarily interested in circulating tumor markers that predict the development and progression of prostate cancer, as well as the possibility that these related markers play a key role in the pathogenesis of prostate cancer. I have contributed to over 180 peer-reviewed scientific publications, primarily detailing the relationship of biomarker proteins, prostate physiology, and pathology. I was a tenured professor at Lund University in Sweden until I moved to Memorial Sloan Kettering Cancer Center, and I still maintain an active relationship with my former laboratory at Lund University.
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicare and New York State Medicaid also provide benefits for care at MSK.Learn more